Abstract:Medical Decision Making, Ahead of Print. BackgroundMulti-indication cancer drugs receive licensing extensions to include additional indications, as trial evidence on treatment effectiveness accumulates. We investigate how sharing information across indications can strengthen the inferences supporting health technology assessment (HTA).MethodsWe applied meta-analytic methods to randomized trial data on bevacizumab, to share information across oncology indications on the treatment effect on overall survival (OS) or progression-free survival (PFS) and on the surrogate relationship between effects on PFS and OS. Common or random indication-level parameters were used to facilitate information sharing, and the further flexibility of mixture models was also explored.ResultsTreatment effects on OS lacked precision when pooling data available at present day within each indication separately, particularly for indications with few trials. There was no suggestion of heterogeneity across indications. Sharing information across indications provided more precise estimates of treatment effects and surrogacy parameters, with the strength of sharing depending on the model. When a surrogate relationship was used to predict treatment effects on OS, uncertainty was reduced only when sharing effects on PFS in addition to surrogacy parameters. Corresponding analyses using the earlier, sparser (within and across indications) evidence available for particular HTAs showed that sharing on both surrogacy and PFS effects did not notably reduce uncertainty in OS predictions. Little heterogeneity across indications meant limited added value of the mixture models.ConclusionsMeta-analysis methods can be usefully applied to share information on treatment effectiveness across indications in an HTA context, to increase the precision of target indication estimates. Sharing on surrogate relationships requires caution, as meaningful precision gains in predictions will likely require a substantial evidence base and clear support for surrogacy from other indications.HighlightsWe investigated how sharing information across indications can strengthen inferences on the effectiveness of multi-indication treatments in the context of health technology assessment (HTA).Multi-indication meta-analysis methods can provide more precise estimates of an effect on a final outcome or of the parameters describing the relationship between effects on a surrogate endpoint and a final outcome.Precision of the predicted effect on the final outcome based on an effect on the surrogate endpoint will depend on the precision of the effect on the surrogate endpoint and the strength of evidence of a surrogate relationship across indications.Multi-indication meta-analysis methods can be usefully applied to predict an effect on the final outcome, particularly where there is limited evidence in the indication of interest.

Bayesian multi-parameter evidence synthesis to inform decision-making: a case study in hormone-refractory metastatic prostate cancer

Multistate Pharmacometric Model to Define the Impact of Second‐Line Immunotherapies on the Survival Outcome of the <scp>IMpower131</scp> Study

Multi-indication Evidence Synthesis in Oncology Health Technology Assessment: Meta-analysis Methods and Their Application to a Case Study of Bevacizumab

Multi-indication evidence synthesis in oncology health technology assessment

Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making

Bayesian meta-analysis for evaluating treatment effectiveness in biomarker subgroups using trials of mixed patient populations

Bayesian meta‐analysis for evaluating treatment effectiveness in biomarker subgroups using trials of mixed patient populations

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches

Bayesian survival extrapolation for cost-effectiveness analysis: a case study of RELAY for ramucirumab in combination with erlotinib in the treatment of non-small-cell lung cancer

Bayesian pairwise meta‐analysis of time‐to‐event outcomes in the presence of non‐proportional hazards: A simulation study of flexible parametric, piecewise exponential and fractional polynomial models

Multivariate network meta-analysis of survival function parameters

Use of copula to model within-study association in bivariate meta-analysis of binomial data at the aggregate level a Bayesian approach and application to surrogate endpoint evaluation

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

Bayesian Hierarchical Models for Meta-Analysis of Quality-of-Life Outcomes: An Application in Multimorbidity

MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial

Predicting Treatment Effects from Surrogate Endpoints in Historical Trials in First-Line Metastatic Castration-Resistant Prostate Cancer

Longitudinal model–based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer

Using Clinical Experts Beliefs to Compare Survival Models in Health Technology Assessment

A flexible multi-metric Bayesian framework for decision-making in Phase II multi-arm multi-stage studies

Using Bayesian Evidence Synthesis Methods to Incorporate Real World Evidence in Surrogate Endpoint Evaluation